Clinical Trial Update: A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravenous immunoglobulin (IGIV) 10% for chronic inflammatory demyelinating polyneuropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• IGIV 10% (intravenous immunoglobulin) (intravenous immunoglobulin)

Snippet

Sponsor: Kedrion S.p.A. | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Status: RECRUITING